Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis (ESWT)
Effectiveness of Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis of the Shoulder: A Randomized Double-Blind Controlled Trial
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Shih-Wei Huang, MD
- Numéro de téléphone: +886970747556
- E-mail: shihwei@tmu.edu.tw
Lieux d'étude
-
-
Taipei
-
Taipei, Taipei, Taïwan, 116
- Recrutement
- Wan Fang Hospital, Taipei Medical University
-
Contact:
- Shih-Wei Huang
- Numéro de téléphone: 0970747556
- E-mail: shihwei@tmu.edu.tw
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age between 20 and 70 years
- Unilateral calcific tendinitis of the shoulder confirmed by clinical physical examination, including a positive Neer's impingement test
- Symptom duration of more than 3 months
- Imaging (radiography and/or high-resolution ultrasound) demonstrating a calcific deposit within a rotator cuff tendon with a maximal diameter greater than 5 mm
- Baseline self-reported pain intensity greater than 4 on the Visual Analog Scale (VAS, 0-10)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Concomitant full-thickness rotator cuff tear
- History of fracture or surgery involving the ipsilateral shoulder
- Coagulopathy, or anticoagulant therapy that cannot be safely discontinued
- Pregnancy or breastfeeding
- Malignancy, particularly involving or adjacent to the shoulder region
- Local infection or skin lesion at the intended treatment site
- Injection therapy to the ipsilateral shoulder within the preceding 6 weeks
- Any other condition that, in the judgment of the investigator, makes the participant unsuitable for participation in the trial
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Ultrasound localization ESWT
Ultrasound image guided the depth and location of calcification point, Perform ESWT for calcific tendonitis of shoulder
|
Use ultrasound guided localization of calcific tendonitis of shoulder and then perform Extracorporeal Shock Wave Therapy, ESWT 0.12 to 0.25 mJ/mm 6000 times
|
|
Comparateur actif: Palpation localization ESWT
Palpation and depends the feedback of participants localization of ESWT points
|
Use palpation localization of calcific tendonitis of shoulder and then perform Extracorporeal Shock Wave Therapy, ESWT 0.12 to 0.25 mJ/mm 6000 times
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Constant-Murley Score (CMS)
Délai: Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
The Constant-Murley Score is a clinician-administered instrument assessing shoulder function across four domains: pain (15 points), activities of daily living (20 points), range of motion (40 points), and strength (25 points), for a total score of 0-100.
Higher scores indicate better shoulder function.
The measure compares real-time high-resolution ultrasound-guided focused ESWT (experimental) with X-ray plus palpation-guided focused ESWT (control) for calcific tendinitis of the shoulder.
Assessed at baseline, Week 4, and Week 12; change from baseline is reported.
|
Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
|
Change in Pain Visual Analog Scale (VAS)
Délai: Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
Pain intensity is self-reported on a 0-10 Visual Analog Scale, where 0 = no pain and 10 = worst imaginable pain.
Ratings are collected for pain at rest, pain with activity, night pain, and average pain over the past week.
Higher scores indicate greater pain.
Change from baseline is compared between the ultrasound-guided ESWT and landmark (X-ray + palpation)-guided ESWT groups.
Assessed at baseline, Week 4, and Week 12.
|
Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
|
Change from Baseline in Shoulder Pain and Disability Index (SPADI)
Délai: Baseline, Week 4, Week 12
|
Patient-reported questionnaire comprising a 5-item pain subscale and an 8-item disability subscale, each item scored 0-10.
Subscale and total scores are expressed as percentages (0-100%), with higher scores indicating greater pain and disability.
|
Baseline, Week 4, Week 12
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Calcific Deposit Resorption Rate
Délai: Baseline, Week 4, Week 12
|
Calcific deposit dimensions (long axis, short axis, area, and estimated volume) are quantified from ultrasound images using ImageJ software.
Percentage volume reduction from baseline is calculated.
Resorption is additionally categorized as complete, partial (>50%), partial (<50%), unchanged, or increased.
|
Baseline, Week 4, Week 12
|
|
Change from Baseline in Shoulder Range of Motion (ROM)
Délai: Baseline, Week 4, Week 12
|
Active and passive range of motion measured in degrees with a goniometer for forward flexion, abduction, external rotation at 90° abduction, and internal rotation at 90° abduction.
|
Baseline, Week 4, Week 12
|
|
Tendon Structural Integrity on Ultrasound
Délai: Baseline, Week 4, Week 12
|
Supraspinatus (or affected) tendon integrity graded on high-resolution ultrasound as intact, partial-thickness tear, or full-thickness tear.
Tendon thickness is recorded in millimeters.
|
Baseline, Week 4, Week 12
|
|
Patient Global Impression of Change (PGIC)
Délai: Week 4, Week 12
|
Single-item 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the participant's overall perceived change since starting treatment.
|
Week 4, Week 12
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- N202604139
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .